301230 泓博医药
已收盘 07-17 15:00:00
资讯
新帖
简况
7月17日泓博医药跌16.34%，长城消费增值混合A基金重仓该股
证券之星 · 07-17 17:00
7月17日泓博医药跌16.34%，长城消费增值混合A基金重仓该股
7月15日泓博医药涨5.06%，长城消费增值混合A基金重仓该股
证券之星 · 07-15 16:37
7月15日泓博医药涨5.06%，长城消费增值混合A基金重仓该股
股市必读：泓博医药（301230）7月10日董秘有最新回复
证券之星 · 07-13
股市必读：泓博医药（301230）7月10日董秘有最新回复
7月10日泓博医药涨13.13%，长城消费增值混合A基金重仓该股
证券之星 · 07-10
7月10日泓博医药涨13.13%，长城消费增值混合A基金重仓该股
7月8日泓博医药跌5.85%，长城消费增值混合A基金重仓该股
证券之星 · 07-08
7月8日泓博医药跌5.85%，长城消费增值混合A基金重仓该股
泓博医药：本次权益分派将在股东会审议通过之日起两个月内实施完毕
证券之星 · 07-08
泓博医药：本次权益分派将在股东会审议通过之日起两个月内实施完毕
泓博医药：截至2026年6月30日股东户数为21,845户
证券之星 · 07-08
泓博医药：截至2026年6月30日股东户数为21,845户
7月7日泓博医药跌6.62%，长城消费增值混合A基金重仓该股
证券之星 · 07-07
7月7日泓博医药跌6.62%，长城消费增值混合A基金重仓该股
7月1日泓博医药涨6.89%，长城消费增值混合A基金重仓该股
证券之星 · 07-01
7月1日泓博医药涨6.89%，长城消费增值混合A基金重仓该股
6月29日泓博医药涨11.97%，长城消费增值混合A基金重仓该股
证券之星 · 06-29
6月29日泓博医药涨11.97%，长城消费增值混合A基金重仓该股
6月26日泓博医药跌5.75%，长城消费增值混合A基金重仓该股
证券之星 · 06-26
6月26日泓博医药跌5.75%，长城消费增值混合A基金重仓该股
6月23日泓博医药涨5.46%，长城消费增值混合A基金重仓该股
证券之星 · 06-23
6月23日泓博医药涨5.46%，长城消费增值混合A基金重仓该股
股市必读：泓博医药（301230）6月17日董秘有最新回复
证券之星 · 06-18
股市必读：泓博医药（301230）6月17日董秘有最新回复
泓博医药：CADD/AIDD技术深度嵌入到业务环节
证券之星 · 06-17
泓博医药：CADD/AIDD技术深度嵌入到业务环节
泓博医药(301230)6月10日股东户数2.05万户，较上期减少0.83%
证券之星 · 06-12
泓博医药(301230)6月10日股东户数2.05万户，较上期减少0.83%
泓博医药：截至2026年6月10日股东户数为20,521户
证券之星 · 06-12
泓博医药：截至2026年6月10日股东户数为20,521户
泓博医药：2025年营业收入及盈利能力均实现同比改善
证券之星 · 06-12
泓博医药：2025年营业收入及盈利能力均实现同比改善
泓博医药：截至2026年5月29日，公司的股东户数为20,692户
证券之星 · 06-10
泓博医药：截至2026年5月29日，公司的股东户数为20,692户
泓博医药（301230）披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市公告，5月28日股价上涨0.36%
证券之星 · 05-28
泓博医药（301230）披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市公告，5月28日股价上涨0.36%
泓博医药（301230）披露2025年度持续督导定期现场检查报告，5月19日股价上涨1.21%
证券之星 · 05-19
泓博医药（301230）披露2025年度持续督导定期现场检查报告，5月19日股价上涨1.21%
公司概况
公司名称：
上海泓博智源医药股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-11-01
主营业务：
上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是药物化学、合成化学、药物代谢动力学、工艺化学、工艺开发、药学研究、定制化生产、自主产品生产。
发行价格：
40.00
{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":28.72,"timestamp":1784271807000,"preClose":34.33,"halted":0,"volume":25033931,"delay":0,"changeRate":-0.1634,"floatShares":163000000,"shares":181000000,"eps":0.2548,"marketStatus":"已收盘","change":-5.61,"latestTime":"07-17 15:00:00","open":33.47,"high":33.65,"low":28.55,"amount":761000000,"amplitude":0.1486,"askPrice":28.73,"askSize":66,"bidPrice":28.72,"bidSize":20,"shortable":0,"etf":0,"ttmEps":0.2548,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784511000000},"marketStatusCode":5,"adr":0,"adjPreClose":34.33,"symbolType":"stock","openAndCloseTimeList":[[1784251800000,1784259000000],[1784264400000,1784271600000]],"highLimit":37.76,"lowLimit":30.9,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":180941126,"isCdr":false,"pbRate":6.03,"roa":"--","peRate":112.715856,"roe":"2.34%","epsLYR":0.25,"committee":0.716535,"marketValue":5197000000,"turnoverRate":0.1538,"status":1,"floatMarketCap":4674000000},"requestUrl":"/m/hq/s/301230/wiki","defaultTab":"wiki","newsList":[{"id":"2652095104","title":"7月17日泓博医药跌16.34%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652095104","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652095104?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278809,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日泓博医药跌16.34%，收盘报28.72元，换手率19.93%，成交量25.03万手，成交额7.61亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455881","title":"7月15日泓博医药涨5.06%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651455881?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:37","pubTimestamp":1784104652,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日泓博医药涨5.06%，收盘报42.15元，换手率17.08%，成交量21.45万手，成交额9.1亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651663701","title":"股市必读：泓博医药（301230）7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651663701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651663701?lang=zh_cn&edition=full","pubTime":"2026-07-13 02:10","pubTimestamp":1783879821,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，泓博医药报收于40.16元，上涨13.13%，换手率14.53%，成交量18.24万手，成交额7.1亿元。董秘最新回复投资者： 你好，请问截至6月30日股东人数，谢谢董秘： 尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年6月30日（交易日），公司的股东户数为21,845户。交易信息汇总资金流向7月10日主力资金净流入383.7万元，占总成交额0.0%；游资资金净流出4617.27万元，占总成交额0.0%；散户资金净流入4233.57万元，占总成交额0.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300001093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183091","title":"7月10日泓博医药涨13.13%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183091","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650183091?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:37","pubTimestamp":1783672641,"startTime":"0","endTime":"0","summary":"证券之星消息，7月10日泓博医药涨13.13%，收盘报40.16元，换手率14.53%，成交量18.24万手，成交额7.1亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649961118","title":"7月8日泓博医药跌5.85%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649961118","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649961118?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:45","pubTimestamp":1783500311,"startTime":"0","endTime":"0","summary":"证券之星消息，7月8日泓博医药跌5.85%，收盘报34.77元，换手率6.82%，成交量8.56万手，成交额3.08亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800029603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649956908","title":"泓博医药：本次权益分派将在股东会审议通过之日起两个月内实施完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2649956908","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649956908?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:48","pubTimestamp":1783471691,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：2025年分红计划四月份就通过了，为什么到现在还没执行？预计什么时候会有结果？泓博医药回复：尊敬的投资者您好！《关于公司2025年度利润分配方案的议案》已于2026年5月19日股东会审议通过，本次权益分派将在股东会审议通过之日起两个月内实施完毕，当前权益分派相关工作正在积极推进，敬请留意近期公告。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800008341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649956577","title":"泓博医药：截至2026年6月30日股东户数为21,845户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649956577","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649956577?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:39","pubTimestamp":1783471157,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，截止到2026年07月02日，公司股东户数是多少？泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年6月30日（交易日），公司的股东户数为21,845户。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800008259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649882799","title":"7月7日泓博医药跌6.62%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649882799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649882799?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:42","pubTimestamp":1783413725,"startTime":"0","endTime":"0","summary":"证券之星消息，7月7日泓博医药跌6.62%，收盘报36.93元，换手率7.68%，成交量9.64万手，成交额3.63亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700027737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516467","title":"7月1日泓博医药涨6.89%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516467?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:55","pubTimestamp":1782896137,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日泓博医药涨6.89%，收盘报39.38元，换手率12.09%，成交量15.19万手，成交额5.73亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322241","title":"6月29日泓博医药涨11.97%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322241?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:54","pubTimestamp":1782723269,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日泓博医药涨11.97%，收盘报38.72元，换手率10.21%，成交量12.82万手，成交额4.82亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646358233","title":"6月26日泓博医药跌5.75%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646358233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646358233?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:02","pubTimestamp":1782464552,"startTime":"0","endTime":"0","summary":"证券之星消息，6月26日泓博医药跌5.75%，收盘报34.58元，换手率5.22%，成交量6.56万手，成交额2.35亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645173881","title":"6月23日泓博医药涨5.46%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645173881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645173881?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:42","pubTimestamp":1782204137,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日泓博医药涨5.46%，收盘报37.09元，换手率8.57%，成交量10.76万手，成交额3.95亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644721725","title":"股市必读：泓博医药（301230）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644721725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644721725?lang=zh_cn&edition=full","pubTime":"2026-06-18 02:49","pubTimestamp":1781722150,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，泓博医药报收于33.53元，下跌0.42%，换手率2.24%，成交量2.81万手，成交额9421.07万元。CADD/AIDD技术作为公司传统研发服务的赋能工具，其价值主要体现在提升服务效率、缩短研发周期、增强复杂分子交付能力等方面，而非直接产生大规模收入。截至2025年12月底，公司CADD/AIDD技术平台已累计为104个新药项目提供技术支持，其中8个项目已进入临床实验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800001897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746701","title":"泓博医药：CADD/AIDD技术深度嵌入到业务环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644746701?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:53","pubTimestamp":1781700785,"startTime":"0","endTime":"0","summary":"CADD/AIDD技术作为公司传统研发服务的赋能工具，其价值主要体现在提升服务效率、缩短研发周期、增强复杂分子交付能力等方面，而非直接产生大规模收入。公司的CADD/AIDD技术深度嵌入到业务环节，价值更多体现在高质量的服务溢价、增加客户粘性及业务渗透率等方面。截至2025年12月底，公司CADD/AIDD技术平台已累计为104个新药项目提供技术支持，其中8个项目已进入临床实验阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700039506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642261339","title":"泓博医药(301230)6月10日股东户数2.05万户，较上期减少0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642261339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642261339?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:36","pubTimestamp":1781257018,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泓博医药披露，截至2026年6月10日公司股东户数为2.05万户，较5月29日减少171.0户，减幅为0.83%。在医疗服务行业个股中，泓博医药股东户数低于行业平均水平，截至6月10日，医疗服务行业平均股东户数为4.82万户。从股价来看，2026年5月29日至2026年6月10日，泓博医药区间跌幅为5.66%，在此期间股东户数减少171.0户，减幅为0.83%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200027750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642259223","title":"泓博医药：截至2026年6月10日股东户数为20,521户","url":"https://stock-news.laohu8.com/highlight/detail?id=2642259223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642259223?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:36","pubTimestamp":1781235367,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，截至6月10日，公司股东人数多少泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年6月10日（交易日），公司的股东户数为20,521户。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200014661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642539722","title":"泓博医药：2025年营业收入及盈利能力均实现同比改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2642539722","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642539722?lang=zh_cn&edition=full","pubTime":"2026-06-12 09:12","pubTimestamp":1781226739,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药06月11日在投资者关系平台上答复投资者关心的问题。公司2025年营业收入及盈利能力均实现同比改善，经营质量持续提升。目前在手订单、项目推进及客户合作情况整体稳定。公司将持续夯实主业基础，提升运营效率与技术能力，不断增强公司的内在价值，致力于为投资者创造长期、可持续的价值回报。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200006252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642147034","title":"泓博医药：截至2026年5月29日，公司的股东户数为20,692户","url":"https://stock-news.laohu8.com/highlight/detail?id=2642147034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642147034?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:34","pubTimestamp":1781062440,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，截至5月31日，公司股东人数多少泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年5月29日（交易日），公司的股东户数为20,692户。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000017330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638914706","title":"泓博医药（301230）披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市公告，5月28日股价上涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638914706","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638914706?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:27","pubTimestamp":1779978433,"startTime":"0","endTime":"0","summary":"近日，上海泓博智源医药股份有限公司发布《关于2024年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市公告》。公告显示，公司于2026年5月28日完成2024年限制性股票激励计划首次授予部分第一个归属期的股份归属登记，本次归属日为2026年5月28日，归属股票数量为308,000股，归属对象为23名激励对象，股票来源为公司从二级市场回购的A股普通股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636834738","title":"泓博医药（301230）披露2025年度持续督导定期现场检查报告，5月19日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636834738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636834738?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:33","pubTimestamp":1779183189,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，泓博医药报收于39.32元，较前一交易日上涨1.21%，最新总市值为54.89亿元。该股当日开盘38.97元，最高39.87元，最低38.89元，成交额达1.65亿元，换手率为3.33%。公告显示，中信证券对泓博医药2025年度持续督导进行了现场检查，检查期间为2025年1月1日至12月31日，现场检查时间为2026年5月12日。现场检查未发现重大问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900032656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784311336697,"stockEarnings":[{"period":"1week","weight":-0.0686},{"period":"1month","weight":0.1156},{"period":"3month","weight":-0.0663},{"period":"6month","weight":-0.1956},{"period":"1year","weight":-0.0276},{"period":"ytd","weight":0.2549}],"compareEarnings":[{"period":"1week","weight":-0.0581},{"period":"1month","weight":-0.0837},{"period":"3month","weight":-0.0709},{"period":"6month","weight":-0.0823},{"period":"1year","weight":0.0703},{"period":"ytd","weight":-0.0516}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"21845人(较上一季度增加6.45%)","perCapita":"7450股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"18094万元","survey":" 上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是药物化学、合成化学、药物代谢动力学、工艺化学、工艺开发、药学研究、定制化生产、自主产品生产。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}